New Republic Capital LLC Has $228,000 Holdings in Novartis AG (NYSE:NVS)

New Republic Capital LLC raised its stake in shares of Novartis AG (NYSE:NVS) by 16.2% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,340 shares of the company’s stock after acquiring an additional 326 shares during the quarter. New Republic Capital LLC’s holdings in Novartis were worth $228,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Union Bancaire Privee UBP SA acquired a new position in Novartis during the fourth quarter valued at approximately $27,000. Legacy Investment Solutions LLC bought a new stake in shares of Novartis during the 3rd quarter worth $28,000. Fortitude Family Office LLC grew its stake in Novartis by 503.8% in the 3rd quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock valued at $37,000 after buying an additional 267 shares during the last quarter. Brooklyn Investment Group bought a new position in Novartis in the 4th quarter worth $55,000. Finally, Golden State Wealth Management LLC acquired a new position in Novartis during the 4th quarter worth $69,000. Institutional investors own 13.12% of the company’s stock.

Novartis Trading Up 0.5 %

Shares of Novartis stock opened at $106.81 on Tuesday. The stock has a market capitalization of $218.31 billion, a P/E ratio of 18.16, a price-to-earnings-growth ratio of 1.70 and a beta of 0.58. Novartis AG has a 12-month low of $92.35 and a 12-month high of $120.92. The company has a quick ratio of 0.90, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The company has a 50-day simple moving average of $100.32 and a 200 day simple moving average of $108.39.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Research analysts expect that Novartis AG will post 8.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NVS has been the topic of a number of recent analyst reports. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Deutsche Bank Aktiengesellschaft upgraded Novartis from a “hold” rating to a “buy” rating in a report on Tuesday, February 4th. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, BMO Capital Markets increased their target price on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Novartis has an average rating of “Hold” and a consensus target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.